MA27497A1 - Compositions ophtalmiques pour le traitement de l'hypertension oculaire. - Google Patents

Compositions ophtalmiques pour le traitement de l'hypertension oculaire.

Info

Publication number
MA27497A1
MA27497A1 MA28316A MA28316A MA27497A1 MA 27497 A1 MA27497 A1 MA 27497A1 MA 28316 A MA28316 A MA 28316A MA 28316 A MA28316 A MA 28316A MA 27497 A1 MA27497 A1 MA 27497A1
Authority
MA
Morocco
Prior art keywords
agent
eye
treatment
vagomimetic
compounds
Prior art date
Application number
MA28316A
Other languages
English (en)
Inventor
James B Doherty
Meng-Hsin Chen
Luping Liu
Swaminathan R Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA27497A1 publication Critical patent/MA27497A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

sous forme de solution ou suspension et contenant facultativement de la gomme xanthane ou de la gomme gellane. 11. Une composition conformément à la Revendication 9 oé un ingrédient actif appartient à la famille consistant de: agent bloquant adrénolytique-(beta), agent para-vagomimétique, agent vagomimétique, inhibiteur de l'anhydrase carbonique, agoniste EP4, une prostaglandine ou un dérivé de celle-ci, lipide hypotenseur, neuroprotecteur, et/ou un agoniste du récepteur 5-HT2 est ajouté. L'invention concerne des composés puissants de blocage du canal de potassium de formule I ou une préparation correspondante destinée au traitement de glaucome ou d'autres troubles qui débouchent sur une pression intraoculaire élevée dans l'oeil d'un patient. Cette invention a aussi trait à l'utilisation de tels composés de manière à engendrer un effet neuroprotecteur destiné à l'oeil d'espèces mammaliennes, notamment, des êtres humains
MA28316A 2002-11-08 2005-06-07 Compositions ophtalmiques pour le traitement de l'hypertension oculaire. MA27497A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42480802P 2002-11-08 2002-11-08
US50009103P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
MA27497A1 true MA27497A1 (fr) 2005-08-01

Family

ID=32314559

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28316A MA27497A1 (fr) 2002-11-08 2005-06-07 Compositions ophtalmiques pour le traitement de l'hypertension oculaire.

Country Status (22)

Country Link
US (2) US7196082B2 (fr)
EP (1) EP1562909B1 (fr)
JP (2) JP4456072B2 (fr)
KR (1) KR20050072805A (fr)
AR (1) AR041991A1 (fr)
AU (2) AU2003287506B8 (fr)
BR (1) BR0316040A (fr)
CA (1) CA2505086C (fr)
CL (1) CL2003002293A1 (fr)
DO (1) DOP2003000747A (fr)
EC (1) ECSP055781A (fr)
HR (1) HRP20050409A2 (fr)
IS (1) IS7822A (fr)
MA (1) MA27497A1 (fr)
MX (1) MXPA05004889A (fr)
NO (1) NO20052751D0 (fr)
NZ (1) NZ539593A (fr)
PE (1) PE20040692A1 (fr)
PL (1) PL377172A1 (fr)
RU (1) RU2005117627A (fr)
TW (1) TWI250873B (fr)
WO (2) WO2004043932A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040028469A (ko) 2002-09-30 2004-04-03 엘지전자 주식회사 1 회 기록 가능한 광디스크의 디펙트 영역 관리방법
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
BRPI0414102A (pt) * 2003-09-04 2006-10-31 Merck & Co Inc composto, uso do mesmo, e, composição
US7563816B2 (en) * 2004-07-20 2009-07-21 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1647549A1 (fr) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles et benzisothiazoles en tant qu'agents oestrogéniques
WO2007089646A1 (fr) * 2006-01-31 2007-08-09 Array Biopharma Inc. Inhibiteurs de kinase et méthodes d'utilisation
WO2007108968A2 (fr) * 2006-03-13 2007-09-27 Merck & Co., Inc. Compositions ophtalmiques pour le traitement de l'hypertension oculaire
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
CA2742306A1 (fr) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Composes pour le traitement de l'osteoporose et de cancers
WO2012071369A2 (fr) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
EP2968303B1 (fr) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, leur préparation et leur utilisation
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
CN111393434B (zh) 2014-04-30 2022-11-04 哥伦比亚大学董事会 取代的4-苯基哌啶及其制备和用途
CN104211638A (zh) * 2014-08-13 2014-12-17 李增 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用
WO2017123826A1 (fr) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Modulateurs de mastocytes et leurs utilisations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
WO1989010757A1 (fr) 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis Nouvelle preparation ophtalmique pour le traitement de glaucomes
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DE68929435T2 (de) 1988-09-06 2003-07-17 Pharmacia Ab, Stockholm Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3208210B2 (ja) * 1993-03-17 2001-09-10 旭化成株式会社 結晶性芳香族ポリカーボネートプレポリマーの製造方法及び芳香族ポリカーボネートの製造方法
EP0724443A4 (fr) 1993-06-08 1997-09-10 Vide Pharmaceuticals Procedes et comositions d'abaissement de la pression intra-oculaire
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
EP1114816A4 (fr) 1998-09-14 2002-09-04 Ono Pharmaceutical Co DERIVES E DE PHENYL-PROSTAGLANDINE A SUBSTITUTION-$g(V) ET MEDICAMENTS LES CONTENANT COMME INGREDIENT ACTIF
AP2002002555A0 (en) 1999-12-22 2002-06-30 Pfizer Prod Inc EP4 Receptor selective agonists in the treatment of osteoporosis.
AU771130B2 (en) 2000-01-18 2004-03-11 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1268438A1 (fr) 2000-03-17 2003-01-02 Alcon, Inc Derives de 6-hydroxy-indazole destines au traitement du glaucome
CA2401959A1 (fr) 2000-03-17 2001-09-27 Alcon, Inc. Derives d'indazole 5-hydroxy permettant de traiter le glaucome
US6956036B1 (en) * 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
WO2001072268A1 (fr) 2000-03-31 2001-10-04 Toray Industries, Inc. Agents de régulation de la pousse du cheveu ou de sa formation
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
EA200300379A1 (ru) 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie

Also Published As

Publication number Publication date
JP4456072B2 (ja) 2010-04-28
PE20040692A1 (es) 2004-10-08
US20040097575A1 (en) 2004-05-20
NZ539593A (en) 2006-12-22
NO20052751L (no) 2005-06-07
NO20052751D0 (no) 2005-06-07
AU2003287506B2 (en) 2009-04-23
CA2505086A1 (fr) 2004-05-27
TWI250873B (en) 2006-03-11
EP1562909B1 (fr) 2012-06-27
RU2005117627A (ru) 2006-01-20
AU2003287506B8 (en) 2009-05-28
US20070129418A1 (en) 2007-06-07
MXPA05004889A (es) 2005-07-22
DOP2003000747A (es) 2004-05-31
PL377172A1 (pl) 2006-01-23
US7196082B2 (en) 2007-03-27
CL2003002293A1 (es) 2005-01-14
AU2003287506A1 (en) 2004-06-03
JP5061293B2 (ja) 2012-10-31
EP1562909A1 (fr) 2005-08-17
KR20050072805A (ko) 2005-07-12
AU2003286884A1 (en) 2004-06-03
WO2004043933A1 (fr) 2004-05-27
ECSP055781A (es) 2005-09-20
US7547720B2 (en) 2009-06-16
JP2006508190A (ja) 2006-03-09
AR041991A1 (es) 2005-06-08
HRP20050409A2 (en) 2006-02-28
BR0316040A (pt) 2005-09-13
IS7822A (is) 2005-04-25
JP2010006825A (ja) 2010-01-14
TW200501949A (en) 2005-01-16
CA2505086C (fr) 2009-08-25
WO2004043932A1 (fr) 2004-05-27

Similar Documents

Publication Publication Date Title
US6723748B2 (en) Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
MA27667A1 (fr) Analogues de la prostaglandine comme antagonistes du recepteur de ep4
MA29684B1 (fr) Composes de spiro-oxindole et utilisations associees en tant qu'agents therapeutiques
MA27452A1 (fr) Derives d'indole servant d'agonistes beta-2
EP1501530A4 (fr) Analogues de la prostaglandine f2 alpha en combinaison avec des antimicrobiens pour le traitement du glaucome
CA2807081C (fr) Solutions de bimatoprost et de timolol sans conservateur
LU91541I2 (fr) latanoprost et ses dérivés pharmaceutiquement acceptables (XALATAN)
JP2005514378A (ja) 高眼圧症の治療方法
MA27443A1 (fr) Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
US6649653B1 (en) 15-fluoro prostaglandins as ocular hypotensives
JP3846537B2 (ja) コンタクトレンズ用装着液
RU2005117627A (ru) Офтальмологические композиции для лечения глазной гипертензии
ES2210018T3 (es) Antagonistas de 5ht-2 para regular la presion intraocular y tratar el glaucoma.
AU2002346671B2 (en) Aminoalkyl-benzofuran-5-OL compounds for the treatment of glaucoma
WO2012102355A1 (fr) Composé bicyclique et son utilisation à des fins médicales
MA27762A1 (fr) Utilisation de derives de 10-hydroxy-10, 11-dihydrocarbamazepine pour le traitement de troubles affectifs
JP2016056207A (ja) プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法
JP2003520245A5 (fr)
WO1995034302A3 (fr) Procede utile pour reduire la pression intraoculaire dans l'×il mammalien a l'aide de composes chelatant le calcium
MA30924B1 (fr) Analogues de pyrazoles
JP2005533055A5 (fr)
ATE289817T1 (de) Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
MA27435A1 (fr) DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH